Serina Therapeutics, Inc. (SER)
- Previous Close
10.00 - Open
9.62 - Bid 5.00 x 1000
- Ask 12.80 x 1000
- Day's Range
9.00 - 9.62 - 52 Week Range
9.00 - 35.71 - Volume
182 - Avg. Volume
5,145 - Market Cap (intraday)
22.983M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date May 13, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Serina Therapeutics, Inc. operates as a pharmaceutical company that develops drugs to treat neurological diseases, cancer, and pain. The company develops a pipeline of partnered programs applying POZ platform to cancer, pain, refractory epilepsy, and movement disorders, such as Parkinson's disease and restless leg syndrome. Its pipeline includes SER-214, a solution for Parkinson's disease/restless leg syndrome; SER-226, a post-operative pain management solution; SER-228 for refractory epilepsy; SER-232 for chemotherapy-induced nausea and vomiting; and polymer poly (2-oxazoline) or POZ drug delivery polymer technology. Serina Therapeutics, Inc. was incorporated in 2006 and is based in Huntsville, Alabama.
serinatherapeutics.comRecent News: SER
Performance Overview: SER
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SER
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SER
Valuation Measures
Market Cap
22.98M
Enterprise Value
22.45M
Trailing P/E
19.25
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
14.32
Financial Highlights
Profitability and Income Statement
Profit Margin
167.11%
Return on Assets (ttm)
-39.79%
Return on Equity (ttm)
594.21%
Revenue (ttm)
3.15M
Net Income Avi to Common (ttm)
5.27M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
7.62M
Total Debt/Equity (mrq)
89.88%
Levered Free Cash Flow (ttm)
-1.82M